TransCode Therapeutics (NASDAQ: RNAZ) announced the appointment of Dr. Michel Janicot as consultant Senior Development Officer, effective immediately. Dr. Janicot brings more than 35 years of global oncology drug-development experience to support the advancement of the company's lead therapeutic candidates, TTX-MC138 and Seviprotimut-L. The company aims to leverage his expertise in RNA biology, preclinical strategy, translational medicine, and early clinical development as it progresses its investigational oncology programs toward later-stage clinical trials.
Dr. Janicot is the founder of JMi ONConsulting, a consultancy specializing in oncology drug development. He previously held senior leadership positions at Rhône-Poulenc Rorer and Janssen, where he contributed to the development of several approved oncology drugs. His extensive background includes deep expertise in RNA biology and translational medicine, which aligns with TransCode's focus on RNA therapeutics. In his new role, Dr. Janicot will guide the company's strategic research and development initiatives, particularly for its proprietary TTX nanoparticle platform.
TransCode Therapeutics is a clinical-stage oncology company dedicated to treating metastatic disease. The company's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. Additionally, TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome challenges in RNA delivery, unlocking therapeutic access to novel genetic targets relevant to various cancers. The appointment of Dr. Janicot is expected to accelerate the development of these candidates.
The full press release is available at https://ibn.fm/TAIIy. For more information about TransCode Therapeutics, including the latest news and updates, visit the company's newsroom at https://ibn.fm/RNAZ.
